Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Follicular Thyroid Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Follicular Thyroid Cancer - Pipeline Review, H1 2015', provides an overview of the Follicular Thyroid Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Thyroid Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Follicular Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Follicular Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Follicular Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Follicular Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Follicular Thyroid Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Follicular Thyroid Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Follicular Thyroid Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Follicular Thyroid Cancer - Overview 7 Pipeline Products for Follicular Thyroid Cancer - Comparative Analysis 8 Follicular Thyroid Cancer - Therapeutics under Development by Companies 9 Follicular Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 10 Follicular Thyroid Cancer - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Follicular Thyroid Cancer - Products under Development by Companies 14 Follicular Thyroid Cancer - Products under Investigation by Universities/Institutes 15 Follicular Thyroid Cancer - Companies Involved in Therapeutics Development 16 AstraZeneca PLC 16 Exelixis, Inc. 17 GlaxoSmithKline plc 18 Novartis AG 19 Pfizer Inc. 20 Follicular Thyroid Cancer - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 27 Drug Profiles 28 cabozantinib s-malate - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 dabrafenib mesylate - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 everolimus - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 sunitinib malate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 tetraiodothyroacetic acid nanoparticle - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 vandetanib - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Follicular Thyroid Cancer - Recent Pipeline Updates 50 Follicular Thyroid Cancer - Dormant Projects 70 Follicular Thyroid Cancer - Product Development Milestones 71 Featured News & Press Releases 71 Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 73 Disclaimer 73
List of Tables Number of Products under Development for Follicular Thyroid Cancer, H1 2015 7 Number of Products under Development for Follicular Thyroid Cancer - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Follicular Thyroid Cancer - Pipeline by AstraZeneca PLC, H1 2015 16 Follicular Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2015 17 Follicular Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 18 Follicular Thyroid Cancer - Pipeline by Novartis AG, H1 2015 19 Follicular Thyroid Cancer - Pipeline by Pfizer Inc., H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 23 Number of Products by Stage and Mechanism of Action, H1 2015 25 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 27 Follicular Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2015 50 Follicular Thyroid Cancer - Dormant Projects, H1 2015 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.